Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT02623998
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 102 participants
- Registry
-
NCT02623998
-
- Other papers using this trial's data
- Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02623998. Randomized; no masking; primary purpose treatment. Start 2016-07-09 (actual); primary completion 2018-09-01 (actual). Results posted on 2022-03-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- insulin glargine
- Intervention (Drug)
- sitagliptin/metformin
- Intervention (Behavioral)
- lifestyle therapy
- Lead sponsor
- Population Health Research Institute
- Collaborator
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02623998- Content hash
8dee205e76453989f2125e991aa1cdd35a4c937e3d6985aedb21d0fc0490c271